Last updated on November 2015

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies


Brief description of study

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies

Detailed Study Description

The purpose of this study is to see if GS-9073 can benefit people with CLL. This study will also investigate the safety of GS-9973 and how weel the drug is tolerated.

Clinical Study Identifier: TX141891

Find a site near you

Start Over

AMITA Health

3040 Salt Creek Lane Arlington Heights, IL USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.